Clinical Trials Sponsored by RenaMed Biologics

Total 1438 results

Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI306 in Participants With Hypercholesterolemia

Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Pelican Therapeutics, Inc.

Terminated

PTX-35 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI362 in Chinese Patients With Type 2 Diabetes

Type 2 Diabetes

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19

COVID-19

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Advanced Cervical Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

Overweight or Obesity

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers

Healthy Male Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Myeloid Tumor

Myeloid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

IBI397 or Combination Therapies in Patients With Advanced Malignancies

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

SCLC

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Advanced Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI353 (Orismilast) in Chinese Healthy Adults

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial

Extranodal NK/T Cell Lymphoma, Nasal Type

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of the Safety and Tolerability of IBI321 in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer

Gastric Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC

Non-small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

Advanced or Metastatic NSCLC

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

NPC

China
Innovent Biologics (Suzhou) Co. Ltd.

Suspended

Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS

Myelodysplastic Syndromes

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab（YERVOY）in Adult Healthy Chinese Male Volunteers

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of IBI302 in Patients With nAMD

Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas

Advanced Malignancies

United States
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma (ORIENT-1)

Relapsed/Refractory Classical Hodgkin's Lymphoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

GVHD,Acute

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis

AS
Yale University
DreaMed

Withdrawn

Real World Evaluation of Advisor Pro in Clinical Practice

Type1diabetes
Bionomics Limited

Completed

A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD) (ATTUNE)

Post-Traumatic Stress Disorder

United States, United Kingdom
BiologicTx, LLC

Unknown

Regional Kidney Paired Donor Exchange in Sensitized Patients

The Rate of Kidney Transplants in Sensitized Patients.

United States
Otologics LLC

Unknown

Middle-Ear Implant With MET V Transducer (Aka MET V System)

Mixed Conductive and Sensorineural Hearing Loss, Bilateral
Artu Biologicals

Completed

Long-term Efficacy and Safety Study With Oralgen Grass Pollen

Allergic Rhinoconjunctivitis

Bulgaria, Lithuania, Czech Republic, Germany, Hungary, Netherlands, Slovakia
IMBiologics Corp.

Not yet recruiting

A Study of IMB-101 in Healthy Volunteers and Participants With Rheumatoid Arthritis

Rheumatoid Arthritis
Bionomics Limited

Completed

A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder (PREVAIL)

Social Anxiety Disorder

United States
Bionomics Limited

Completed

A Study of BNC210 in Elderly Patients With Agitation

Agitation in the Elderly

Australia
Bionomics Limited

Completed

Phase II Study of BNC210 in PTSD (RESTORE)

Post-Traumatic Stress Disorder

United States, Australia
Biological Dynamics

Unknown

TR(ACE) Assay Clinical Specimen Study

Breast Neoplasms | Carcinoma, Non-Small-Cell Lung

United States
Artu Biologicals

Completed

Efficacy and Safety of Grass Pollen Sublingual Immunotherapy

Allergic Rhinoconjunctivitis

Bulgaria, Lithuania, Czech Republic, Germany, Hungary, Netherlands, Slovakia
Artu Biologicals

Unknown

A Randomised, Double-blind, Placebo Controlled Study With Oralgen Grass Pollen Rhinoconjunctivitis

Allergic Rhinoconjunctivitis

Netherlands, United Kingdom, Germany, Poland, Belgium, France
Trevena Inc.
Kestrel Biologic

Terminated

A Pilot Study of TRV130 for the Treatment of Fracture Pain

Pain

United States
Immunovative Therapies, Ltd.
Mirror Biologics, Inc.

Recruiting

Immunotherapy for Third Line Metastatic Colorectal Cancer (STIMVAX)

Metastatic Colorectal Cancer

United States
Biocon Biologics UK Ltd

Active, not recruiting

Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis (DEVOTE)

Postmenopausal Women With Osteoporosis

United Kingdom
Apeiron Biologics
Apeiron Respiratory Therapies GmbH

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled APN01 Developed as Treatment for COVID-19

Covid19

Austria
University Hospital, Ghent
Janssen Biologics B.V.

Completed

Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria (CRESPA)

Peripheral Spondylarthritis

Belgium
Axolotl Biologix

Terminated

Evaluating Intra-articular Injection of Axolotl Ambient Compared to Saline in Subjects With Ankle Osteoarthritis (Phoenix)

Ankle Osteoarthritis

United States
Spire, Inc.
ResMed

Completed

An Exploratory, Observational, Non-interventional, Open Label, Remote Pilot Study to Assess Adherence in COPD Subjects

Severe Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary Disease

United States

3

Subscribe